1) Uccioli L, Izzo V, Meloni M, et al. Non-healing foot ulcers in diabetic patients:general and local interfering conditions and management options with advanced wound dressings. J Wound Care 2015;24(4 Suppl):35-42.
2) Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen 2006;14(5):558-65.
3) Miao M, Niu Y, Xie T, et al. Diabetes-impaired wound healing and altered macrophage activation:a possible pathophysiologic correlation. Wound Repair Regen 2012;20(2):203-13.
4) Tanaka R, Wada M, Kwon SM, et al. The effects of flap ischemia on normal and diabetic progenitor cell function. Plast Reconstr Surg 2008;121(6):1929-42.
5) 田端泰彦(編).進みつづける細胞移植治療の実際—再生医療の実現に向けた科学・技術と周辺要素の理解(上下巻).大阪:メディカル ドゥ;2008.
6) Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes:the formation of keratinizing colonies from single cells. Cell 1975;6(3):331-43.
7) Shevchenko RV, James SL, James SE. A review of tissue-engineered skin bioconstructs available for skin reconstruction. J R Soc Interface 2010;7(43):229-58.
8) Cuono C, Langdon R, McGuire J. Use of cultured epidermal autografts and dermal allografts as skin replacement after burn injury. Lancet 1986;1(8490):1123-4.
9) Paggiaro AO, Bastianelli R, Carvalho VF, et al. Is allograft skin, the gold-standard for burn skin substitute? A systematic literature review and meta-analysis. J Plast Reconstr Aesthet Surg 2019;72(8):1245-53.
10) Matsumura H, Matsushima A, Ueyama M, et al. Application of the cultured epidermal autograft “JACE®” for treatment of severe burns:Results of a 6-year multicenter surveillance in Japan. Burns 2016;42(4):769-76.
11) Nihsen ES, Johnson CE, Hiles MC. Bioactivity of small intestinal submucosa and oxidized regenerated cellulose/collagen. Adv Skin Wound Care 2008;21(10):479-86.
12) Kanazawa S, Fujiwara T, Matsuzaki S, et al. bFGF regulates PI3-kinase-Rac1-JNK pathway and promotes fibroblast migration in wound healing. PLoS One 2010;5(8):e12228. doi:10.1371/journal.pone.0012228.
13) Morishita R. Recent progress in gene therapy for cardiovascular disease. Circ J 2002;66(12):1077-86.
14) 厚生労働省.各種申請書作成支援サイト.http://saiseiiryo.mhlw.go.jp/(2021年9月13日アクセス)
15) 佐藤有里,村川史高,井上正範・他.多血小板血漿の臨床応用に向けての実用化の検討 分取法・保存・輸送について.聖マリアンナ医大誌2014;42(3):121-8.
16) Steed DL, Goslen JB, Holloway GA, et al. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992;15(11):1598-604.
17) Senet P, Bon FX, Benbunan M, et al. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. J Vasc Surg 2003;38(6):1342-8.
18) De Vriese AS, Billiet J, Van Droogenbroeck J, et al. Autologous transplantation of bone marrow mononuclear cells for limb ischemia in a caucasian population with atherosclerosis obliterans. J Intern Med 2008;263(4):395-403.
19) Kawamoto A, Asahara T, Losordo DW. Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc Radiat Med 2002;3(3-4):221-5.
20) Tanaka R, Masuda H, Kato S, et al. Autologous G-CSF mobilized peripheral blood CD34+ cell therapy for diabetic patients with chronic nonhealing ulcer. Cell Transplant 2012;23(2):167-79.
21) Tepper OM, Capla JM, Galiano RD, et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 2005;105(3):1068-77.
22) Tanaka R, Ito-Hirano R, Fujimura S, et al. Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing. Stem Cells Transl Med 2021;10(6):895-909.